Create a narrative

Avadel Pharmaceuticals Community

NasdaqGM:AVDL Community

1 Narratives written by author
0 Comments on narratives written by author
15 Fair Values set on narratives written by author

Create a narrative

Avadel Pharmaceuticals

AN

AnalystConsensusTarget

Consensus Narrative from 10 Analysts

LUMRYZ And REVITALYZ Trials Will Unlock Future Value

Key Takeaways LUMRYZ's strong market penetration and $1 billion opportunity hint at future revenue growth, with competitive advantage over peers. Favorable litigation outcomes and Phase III IH trial expansion could enhance revenue and stabilize earnings amidst increased prescriber engagement.

US$17.50

FV

n/a

32.96%

Revenue growth p.a.

0

0

0

New